00:19 , Mar 7, 2018 |  BC Extra  |  Company News

Management tracks: Alliance, Anika

Alliance Pharma plc (LSE:APH) said CEO John Dawson will step down, effective May 1. He will be succeeded by Deputy CEO Peter Butterfield. The company also said Chairman Andrew Smith has stepped down. Smith is...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Duchesnay, Alliance Pharma deal

The partners added Germany, France, Italy and six additional undisclosed EU countries to a 2015 deal granting Alliance rights to market Diclectin doxylamine/pyridoxine in the U.K. Alliance said it will pay L1 million ($1.3 million)...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Lucassin terlipressin: Phase III started

Mallinckrodt began the double-blind, placebo-controlled, North American Phase III CONFIRM trial to evaluate 1 mg IV Lucassin every 6 hours in about 300 patients. Lucassin is approved outside the U.S. and Canada to treat Type...
07:00 , Jun 2, 2014 |  BC Week In Review  |  Company News

Alliance Pharma board of directors update

Alliance Pharma plc (LSE:APH), Chippenham, U.K.   Business: Neurology, Cardiovascular, Dermatology   Appointed: Andrew Smith, a director, as chairman; he succeeds Michael Gatenby  ...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Alliance Pharma, Bayer sales and marketing update

Alliance Pharma's Alliance Pharmaceuticals Ltd. subsidiary acquired from Bayer rights to Irenat sodium perchlorate monohydrate in Germany to diagnose and treat hyperthyroidism. The product marketed in the country, where it had sales of €800,000 ($1.1...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Financial News

Alliance Pharma completes debt financing

Alliance Pharma plc (LSE:APH), Chippenham, U.K.   Business: Neurology, Cardiovascular, Dermatology   Date completed: 10/11/13   Type: Debt financing   Raised: £25 million ($39.9 million)   Investors: Lloyds Bank; Royal Bank of Scotland   Note:...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Alliance Pharma, Novartis sales and marketing update

Alliance's Alliance Pharmaceuticals Ltd. subsidiary acquired all rights to Syntometrine oxytocin/ergometrine from Novartis for $11.5 million. Alliance already had rights to the product in the U.K. under a 2006 deal. The combination of oxytocin and...
00:11 , Aug 18, 2012 |  BC Extra  |  Politics & Policy

ABPI sets team for value-based pricing negotiations

The Association of the British Pharmaceutical Industry announced the members of a team that will negotiate with the U.K.'s Department of Health for the country's proposed value-based pricing system. John Kearney, U.K. and Ireland general...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Alliance Pharma, AstraZeneca sales and marketing update

Alliance said its Alliance Pharmaceuticals Ltd. subsidiary acquired antimalarial drugs Paludrine proguanil, Avloclor chloroquine and Savarine progaunil/chloroquine from AstraZeneca for £4.2 million ($6.6 million) in cash and up to £1 million ($1.6 million) in sales...
07:00 , Mar 19, 2012 |  BC Week In Review  |  Financial News

Sosei completes private placement of preferred stock

Sosei Group Corp. (Tokyo:4565), Tokyo, Japan   Business: Endocrine/Metabolic, Pulmonary, Neurology   Date completed: 3/8/12   Type: Private placement of preferred stock   Raised: ¥300 million ($3.7 million)   Shares: 300   Price: ¥1,000,000  ...